BridgeBio Pharma, Inc. 4

CEO Neil Kumar had 71,217 RSUs in BridgeBio Pharma convert into common stock and 36,237 shares withheld/sold at $79.86 for taxes, increasing his direct holdings to 278,307 shares post-transaction.

On August 16, 2026, BridgeBio Pharma, Inc. CEO Neil Kumar reported the vesting and settlement of multiple tranches of restricted stock units (RSUs) into common stock and a related tax withholding sale. Four RSU conversion transactions (coded “M”) delivered a total of 71,217 shares of common stock to him at no exercise price, increasing his direct holdings at various points to 276,871, 296,470, 308,024, and 314,544 shares, respectively. In connection with these vestings, 36,237 shares of common stock were withheld or disposed of at a price of $79.86 per share (Form 4 code “F”) to satisfy tax obligations, leaving him with 278,307 directly held shares afterward. In addition to his direct ownership, Kumar reports indirect beneficial ownership through several trusts, including 515,686 shares held by the Kumar Haldea Family Irrevocable Trust, 3,568,447 shares held by the Kumar Haldea Revocable Trust, and 750,000 shares held by the NK 2026 GRAT, with disclaimers as to beneficial ownership beyond his pecuniary interest. Overall, the filing reflects routine equity compensation vesting and associated tax-related share withholding rather than an open-market purchase or discretionary sale.

Filing Facts

CIK

1743881

Ticker

BBIO

Form

4

Source Type

fda

Accession

0001470831-26-000836

Alert Tier

5